
    
      This is a phase 2, multi-center, randomized study (n=82, 1:1 MSC:placebo) where consented
      patients will receive 4 intravenous doses of IMP over a period of 2 weeks. Patients must
      provide written informed consent and meet the all Inclusion Criteria and none of the
      Exclusion Criteria to be eligible. Screening procedures include obtaining medical history,
      current medications, questionnaires, vital signs, Chest Xray, 6 Minute walk test and blood
      tests. Historical chest CT and full lung function from 12 weeks prior to screening may be
      used. Bronchoscopy with biopsy must have been performed no more than 6 months prior to
      screening. A bronchoscopy with bronchoalveolar lavage (BAL) is required, however will not
      need to be repeated if performed within 14 days prior to the baseline visit. Patients will
      then receive 4 infusions of MSC/placebo over a period of 2 weeks, with follow up at Week
      3,6,10,14,28,41 and week 54.
    
  